COGT - Cogent Biosciences: Inflection Year Directly Ahead
2024-06-23 06:18:15 ET
Summary
- Today, we revisit clinical stage biotech firm Cogent Biosciences for the first time since 2022.
- The company is heading into the potential inflection year in 2025 and top line results from three late-stage trials should be out during the year.
- Cogent Biosciences is also well funded and enjoys solid support from the analyst community.
- An updated analysis follows in the paragraphs below.
Today, we are putting Cogent Biosciences ( COGT ) in the spotlight for the first time since our look at this clinical stage biotech concern back in September 2022. Updated data from a late-stage study in late May gave the stock a bit of a boost. Can the rally continue? An updated analysis follows below....
Cogent Biosciences: Inflection Year Directly Ahead